BIOMAT Database Logo BIOMAT Database Logo

[Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls]. 1993

U Beiteke, and P Ruppert, and C Garbe, and R Oxenfarth, and I Kastl, and T Türker, and H Tronnier, and P J Frosch
Hautklinik der Städtischen Kliniken Dortmund.

In the dermatological department of Dortmund's Municipal Medical Centre, between May 1986 and April 1991 a total of 105 patients with primary malignant melanoma (stage I) underwent adjuvant treatment with 5 million IU natural interferon beta as a 30-min i.v. infusion three times weekly for 6 months. During follow-up the patients were examined at short intervals and all recurrences and disease-related cases of death were documented up to September 1992. We evaluated the outcome of patients treated with interferon beta (n = 96 with valid notes of tumour thickness) compared with untreated historical controls (n = 288) matched for tumour thickness, localization, and sex, taken from the Central Malignant Melanoma Registry (CMMR) of the German Dermatological Society. Therefore, the main prognostic factors were identical between cases and controls. A computerized randomization was used to fit three control patients to each treated patient. Survival rate and recurrence-free survival were estimated in both groups for a period of 5 years. During the follow-up 3 patients died in the interferon beta group and the 5-year survival rate was 95%, as against 89% in the control group (P < 0.05 for difference between survival curves). Recurrence-free survival curves were also more favourable for interferon-treated patients than for the control group (P = 0.06). A detailed analysis of high-risk patients with tumour thickness of over 1.5 mm also demonstrated obviously better survival (5 years: 95% vs 77%; P = 0.012) and recurrence-free survival rates (5 years: 75% vs 53%; P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

U Beiteke, and P Ruppert, and C Garbe, and R Oxenfarth, and I Kastl, and T Türker, and H Tronnier, and P J Frosch
[Comment on the contribution by U. Beiteke et al. Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. First comment].
March 1994, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
U Beiteke, and P Ruppert, and C Garbe, and R Oxenfarth, and I Kastl, and T Türker, and H Tronnier, and P J Frosch
[Comment on the contribution by U. Beiteke et al. Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Second comment].
March 1994, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
U Beiteke, and P Ruppert, and C Garbe, and R Oxenfarth, and I Kastl, and T Türker, and H Tronnier, and P J Frosch
[Adjuvant interferon therapy in malignant melanoma].
June 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG,
U Beiteke, and P Ruppert, and C Garbe, and R Oxenfarth, and I Kastl, and T Türker, and H Tronnier, and P J Frosch
Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta.
October 1994, Cancer immunology, immunotherapy : CII,
U Beiteke, and P Ruppert, and C Garbe, and R Oxenfarth, and I Kastl, and T Türker, and H Tronnier, and P J Frosch
[Interferon: therapy in patients with cutaneous malignant melanoma in adjuvant setting].
July 2003, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
U Beiteke, and P Ruppert, and C Garbe, and R Oxenfarth, and I Kastl, and T Türker, and H Tronnier, and P J Frosch
Adjuvant therapy of high-risk malignant melanoma patients with gamma interferon.
April 1989, Journal of the American Academy of Dermatology,
U Beiteke, and P Ruppert, and C Garbe, and R Oxenfarth, and I Kastl, and T Türker, and H Tronnier, and P J Frosch
Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients.
May 1991, Cancer,
U Beiteke, and P Ruppert, and C Garbe, and R Oxenfarth, and I Kastl, and T Türker, and H Tronnier, and P J Frosch
Low frequency of neutralizing antibodies against natural interferon-beta during adjuvant therapy for Japanese patients with melanoma.
April 1999, Journal of dermatological science,
U Beiteke, and P Ruppert, and C Garbe, and R Oxenfarth, and I Kastl, and T Türker, and H Tronnier, and P J Frosch
Adjuvant reactivity predicts survival in patients with "high-risk" primary malignant melanoma treated with systemic BCG. EORTC Malignant Melanoma Cooperative Group Writing Committee.
November 1981, International journal of cancer,
U Beiteke, and P Ruppert, and C Garbe, and R Oxenfarth, and I Kastl, and T Türker, and H Tronnier, and P J Frosch
The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy.
January 2015, Medical oncology (Northwood, London, England),
Copied contents to your clipboard!